217 results on '"Bilzer, M"'
Search Results
2. Glutathion reduziert den Ischämie-Reperfusionsschaden nach Transplantation verfetteter Lebern in einem Modell der experimentellen Rattenlebertransplantation
3. 52-jähriger Patient mit subkutaner Raumforderung unter Immunsuppression
4. Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. (Liver and Biliary Disease)
5. Real-world efficacy of elbasvir/grazoprevir in HCV GT1 infected diabetics: results from the German Hepatitis C Registry
6. Real-world efficacy of EBR/GZR in HCV GT1 patients with multiple comorbidities and medications: results from the DHC-R
7. p38 MAPK-vermittelte Resistenz der Leber gegen H2O2: Ein neues Konzept der Hepatoprotektion durch ischämische Präkonditionierung
8. p38 MAPK-vermittelte Resistenz der Leber gegen H2O2: Ein neues Konzept der Hepatoprotektion durch ischämische Präkonditionierung
9. Reply: Carbohydrate deficient transferrin is not a useful marker for the detection of chronic alcohol abuse
10. GLUTATHIONE PROTECTS AGAINST KUPFFER CELL (KC)-MEDIATED LIVER INJURY
11. High effectiveness of elbasvir/grazoprevir (EBR/GZR) treatment in patients with HCV genotype 1a (GT1a) infection in German real-world: results from the German Hepatitis C Registry (DHC-R)
12. High real-world effectiveness of elbasvir/grazoprevir (EBR/GZR) in PWID on opioid substitution therapy with HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R)
13. High real-world effectiveness of elbasvir/grazoprevir (EBR/GZR) in a HCV genotype 1 (GT1) population with a migration background and predominant subtype 1b infection: results from the German Hepatitis C Registry (DHC-R)
14. High real-world efficacy of elbasvir/grazoprevir (EBR/GZR) in genotype 1 (GT1) infected patients with and without liver cirrhosis: results from the German Hepatitis C Registry (DHC-R)
15. Carbohydrate-deficient transferrin is not a useful marker for the detection of chronic alcohol abuse
16. REDOX-SENSITIVE TRANSCRIPTION FACTORS NF-κB AND AP-1 ARE INVOLVED IN THE HEPATIC PROTECTION FROM ISCHEMIA-REPERFUSION INJURY (IRPI) BY THE ATRIAL NATRIURETIC PEPTIDE (ANP)
17. REDUCTION OF KUPFFER CELL-INDUCED OXIDANT INJURY OF THE RAT LIVER BY ATRIAL NATRIURETIC PEPTIDE AND CYCLO-GMP RECEPTOR PROTEINS
18. Utilization of elbasvir/grazoprevir (EBR/GZR) and adoption of resistance associated substitutions (RAS) testing in real-world treatment of HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R)
19. Utilization of elbasvir/grazoprevir (EBR/GZR) and adoption of resistance associated substitutions (RAS) testing in real-world treatment of HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R)
20. Co-morbidities and risk for drug-drug-interactions in HCV GT 1 patients treated with elbasvir/grazoprevir from the German Hepatitis C Registry (DHC-R)
21. Low frequency of drug-drug interactions (DDIs) with the novel all oral antivirals elbasvir (EBV) and grazoprevir (GRZ) in patients with HCV genotype 1 infection in German real-world
22. Boceprevir triple therapy of chronic HCV genotype 1 (G1) infection in previously untreated patients: Efficacy, predictability of virologic response and safety in German real-life
23. Efficacy and safety of Boceprevir triple therapy in previously treated patients with HCV Genotype 1 (G1) infection in German real-life
24. Pre-existing co-morbidities and co-medications of patients undergoing treatment of chronic HCV G1 infection in German real-life
25. Treatment of chronic HCV Genotype 1 infection with Boceprevir in German real-life:The impact of SVR on initially elevated and initially normal serum alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase (GGT) levels
26. Carbohydrate-deficient transferrin is not a useful marker for the detection of chronic alcohol abuse
27. THU-321 - Utilization of elbasvir/grazoprevir (EBR/GZR) and adoption of resistance associated substitutions (RAS) testing in real-world treatment of HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R)
28. Gender-dependent differences in the efficacy and safety of Boceprevir triple therapy in German real-life
29. Current evaluation of the patient with chronic HCV genotype 1 infection before antiviral treatment in German routine clinical practice
30. Boceprevir triple therapy of HCV genotype 1 (G1) infection in German real-life: comparable high SVR rates up to 87% in treatment-naïve and previously treated patients who achieve an early virologic response
31. Gender- and age-related co-morbidities of patients undergoing treatment of chronic HCV G1 infection in German real-life
32. Serum gamma-glutamyl transferase (GGT) levels within the normal range are associated with a high SVR rate of 85% in treatment-naive patients undergoing Boceprevir triple therapy for HCV genotype 1 (G1) infection in German real-world
33. Baseline predictors of an early virologic response (EVR) in previously untreated patients undergoing boceprevir (BOC) triple therapy for HCV genotype 1 infection in German real-life
34. Current clinical evaluation of the patient with HCV genotype 1 infection before antiviral treatment in German routine clinical practice
35. Treatment of previously untreated patients with chronic HCV genotype 1 infection with boceprevir in German real-life: high end of treatment response of 95% in patients with early virologic response
36. Baseline gamma-GT levels within the normal range predict high virologic response rates in treatment-naïve patients undergoing boceprevir triple therapy for HCV genotype 1 (G1) infection
37. Renal impairment under triple therapy with boceprevir in German real-life: evidence for a pivotal role for peginterferon/ribavirin backbone, female gender and age elder than 50 years
38. Female gender, age elder than 50 years and a reduced glomerular filtration rate (eGFR) at baseline strongly predict the frequency of anemia in patients undergoing boceprevir triple therapy in German real-life
39. Tacrolimus als Rinse Solution verringert den Ischämie-Reperfusionsschaden nach experimenteller Lebertransplantation
40. Considerable efficacy of retreatment of chronic Hepatitis C Genotype 1 (G1) Infection with Boceprevir (Victrelis®) in German Real-Life: Interim results from the ongoing Novus study
41. Treatment of chronic Hepatitis C Genotype 1 (G1) infection with Boceprevir (BOC) in German Real-Life: Impact of Hemoglobin (Hb) decline on virologic response
42. Treatment of previously untreated patients with chronic HCV genotype 1 infection with Boceprevir (BOC) in German real-life: High efficacy in patients with early virologic response
43. High virologic response rate at End of Treatment (EOT) following triple therapy of previously untreated HCV Genotype 1 (G1) infection with boceprevir in German real-life
44. P1137 TREATMENT OF CHRONIC HCV GENOTYPE 1 (G1) INFECTION WITH BOCEPREVIR IN GERMAN REAL-LIFE: HIGH EFFICACY TOGETHER WITH MODERATE TREATMENT DISCONTINUATION RATES IN TREATMENT-NAIVE PATIENTS
45. Role of G-protein-coupled Adenosine Receptors in Downregulation of Inflammation and Protection from Tissue Damage
46. Leukocytes decline > 2500/µl during Peginterferon Alfa-2B (PEG-2B)/Ribavirin (RBV) treatment predicts favorable SVR rates in difficult-to-treat patients with HCV Genotype 1 (G1) infection in real-life
47. Treatment of chronic hepatitis C by Pegylated Interferon Alfa-2b (Peg2b) and Ribavirin (RBV): Age-and gender dependent frequency of hematological alterations in a German real-life cohort
48. Treatment of chronic hepatitis C Genotype 1 (G1) infection with boceprevir (Victrelis®) in the German real-life setting: First results for treatment-naïve patients from the Novus observational study
49. Changes of demographic- and disease characteristics of patients with chronic HCV genotype 1 infection In Germany during the past decade
50. Thyroid dysfunction induced by peginterferon alfa-2b (Peg-2b)/Ribavirin (Rbv) is associated with higher SVR rates in patients with HCV Genotype 1 (G1) infection due to improved early virologic response at week 4 and week 12
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.